Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 17/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 17/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 16/20 | 0.43 |
| ▸ | CDK2 | P24941 | 16/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 16/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.43 |
| ▸ | MGMT | P16455 | 4/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8830293 | 0.85 | CDK1 (0.60) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL880169 | 0.84 | CDK1 (0.61) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8537496 | 0.84 | CDK1 (0.44) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL12227596 | 0.82 | CDK1 (0.42) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8618497 | 0.81 | CDK1 (0.44) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL31570032 | 0.80 | PDPK1 (0.33) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL13369897 | 0.80 | PDPK1 (0.33) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Methylguanine SCHEMBL29968306 | 0.78 | CDK1 (0.41) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Methylguanine SCHEMBL1336757 | 0.78 | CDK1 (0.41) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL821881 | 0.77 | CDK1 (0.46) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | AVENTIS PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030004345-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | CASARA PATRICK (FR) | 2003-01-02 | — | — | US | disclosed |
| EP-0701562-B1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL PHARMA INC (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0701562-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMA (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994022882-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0618214-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | TYMP, NUDT1, PNP | CDK1 521/4885CCNB1 825/4885CCNA2 822/4885 |
| US-20030004345-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | TYMP, NUDT1, PNP | CDK1 521/4885CCNB1 825/4885CCNA2 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.